

# Epizyme Inc (EPZM) - Strategic SWOT Analysis Review

<https://marketpublishers.com/r/EAE382F0D55EN.html>

Date: August 2019

Pages: 42

Price: US\$ 125.00 (Single User License)

ID: EAE382F0D55EN

## Abstracts

Epizyme Inc (EPZM) - Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

## Scope

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – GlobalData's summarization of the company's business strategy.

SWOT analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

## Highlights

Epizyme, Inc. (Epizyme) is a biopharmaceutical company that develops novel epigenetic therapies for the treatment of cancer and other disorders. Its lead product candidate tazemetostat is a first-in-class EZH2 inhibitor finds application in hematological malignancies and solid tumors as a monotherapy and combination therapy in relapsed or refractory non-Hodgkin lymphoma. The company's other pipeline products include EZM8266 for sickle cell disease; protein arginine methyltransferase (PRMT) inhibitors for solid tumors, B

cell lymphoma and blood cancer; Pinometostat for acute leukemia. The company develops products through proprietary drug discovery platform and collaborations with other companies. Epizyme is headquartered in Cambridge, Massachusetts, the US.

### Epizyme Inc Key Recent Developments

Aug 09,2019: Epizyme reports business progress and second quarter 2019 results

Jul 22,2019: Epizyme strengthens leadership team with appointment of Paolo Tombesi as chief financial officer

May 06,2019: Epizyme provides business update and reports first quarter 2019 financial results

Feb 26,2019: Epizyme provides business update and reports fourth quarter and full year 2018 financial results

Nov 19,2018: Boehringer partners with Epizyme to develop new cancer therapies

## Reasons to Buy

Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.

Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services and business strategy.

Understand and respond to your competitors' business structure and strategies with GlobalData's detailed SWOT analysis. In this, the company's core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.

Examine potential investment and acquisition targets with this report's detailed insight into the company's strategic, business and operational performance.

**Note:** Some sections may be missing if data is unavailable for the company.

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

- Epizyme Inc - Key Facts
- Epizyme Inc - Key Employees
- Epizyme Inc - Key Employee Biographies
- Epizyme Inc - Major Products and Services
- Epizyme Inc - History
- Epizyme Inc - Company Statement
- Epizyme Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries

### **SECTION 2 – COMPANY ANALYSIS**

- Company Overview
- Epizyme Inc - Business Description
- R&D Overview
- Epizyme Inc - Corporate Strategy
- Epizyme Inc - SWOT Analysis
- SWOT Analysis - Overview
- Epizyme Inc - Strengths
- Epizyme Inc - Weaknesses
- Epizyme Inc - Opportunities
- Epizyme Inc - Threats
- Epizyme Inc - Key Competitors

### **SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

- Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
- Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
- Epizyme Inc, Recent Deals Summary

### **SECTION 4 – COMPANY’S RECENT DEVELOPMENTS**

- Aug 09, 2019: Epizyme reports business progress and second quarter 2019 results
- Jul 22, 2019: Epizyme strengthens leadership team with appointment of Paolo Tombesi as chief financial officer

May 06, 2019: Epizyme provides business update and reports first quarter 2019 financial results

Feb 26, 2019: Epizyme provides business update and reports fourth quarter and full year 2018 financial results

Nov 19, 2018: Boehringer partners with Epizyme to develop new cancer therapies

Nov 02, 2018: Epizyme reports third quarter 2018 financial results and Tazemetostat progress

Aug 02, 2018: Epizyme reports second quarter 2018 financial results and provides business updates

Jul 23, 2018: Epizyme names Dr. Shefali Agarwal as Chief Medical Officer

May 08, 2018: Epizyme Reports First Quarter 2018 Financial Results and Provides Business Updates

Mar 13, 2018: Epizyme Reports Fourth Quarter and Full Year 2017 Financial Results

## **SECTION 5 – APPENDIX**

Methodology

About GlobalData

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Epizyme Inc, Key Facts

Epizyme Inc, Key Employees

Epizyme Inc, Key Employee Biographies

Epizyme Inc, Major Products and Services

Epizyme Inc, History

Epizyme Inc, Subsidiaries

Epizyme Inc, Key Competitors

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Epizyme Inc, Recent Deals Summary

## List Of Figures

### LIST OF FIGURES

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Epizyme Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

### COMPANIES MENTIONED

Takeda Pharmaceutical Co Ltd

Pfizer Inc

Novartis AG

Merck & Co Inc

Eisai Inc

Daiichi Sankyo Co Ltd

Constellation Pharmaceuticals Inc

Celgene Corp

## I would like to order

Product name: Epizyme Inc (EPZM) - Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/EAE382F0D55EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EAE382F0D55EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970